Small molecule inhibitors were applied to STAM mice for investigating whether inhibition of the LPL/FABP4/CPT1 axis could prevent the occurrence of NASH-related HCC in vivo. Here, CPT1A is linked to metabolic dysfunction-associated steatohepatitis.